Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV2-ND4 gene therapy in LHON
NCT03428178Unknown
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Open-label trial of esonadogene mvoparvovec in Leber hereditary optic neuropathy (LHON). Primary endpoint: Best Corrected Visual Acuity at 12 months. Status: unknown.
02
Drugs
esonadogene mvoparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT03428178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428178.